Skip to Content
MilliporeSigma

R9281

Sigma-Aldrich

Rotigotine hydrochloride

≥98% (HPLC)

Synonym(s):

(−)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol hydrochloride, (−)-N 0437, N 0923, Neupro, SPM 962

Slide 1 of 1
Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
$115.00
25 MG
$444.00

$115.00

Check Cart for Availability
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C19H25NOS·HCl
CAS Number:
125572-93-2
Molecular Weight:
351.93
MDL number:
MFCD00906149
UNSPSC Code:
12352200
PubChem Substance ID:
329824046
NACRES:
NA.77

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥98% (HPLC)

form

solid

storage condition

desiccated

color

white to off-white

solubility

DMSO: >10 mg/mL

originator

UCB Inc.

storage temp.

room temp

SMILES string

Cl.CCCN(CCc1cccs1)[C@H]2CCc3c(O)cccc3C2

InChI

1S/C19H25NOS.ClH/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21;/h3-7,13,16,21H,2,8-12,14H2,1H3;1H/t16-;/m0./s1

InChI key

CEXBONHIOKGWNU-NTISSMGPSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
Y00020051606079T1330
Rotigotine hydrochloride ≥98% (HPLC)

Sigma-Aldrich

R9281

Rotigotine hydrochloride

Rotigotine hydrochloride European Pharmacopoeia (EP) Reference Standard

Y0002005

Rotigotine hydrochloride

USP

USP

1606079

Rotigotine Hydrochloride

Tamsulosin hydrochloride ≥98% (HPLC)

Sigma-Aldrich

T1330

Tamsulosin hydrochloride

assay

≥98% (HPLC)

assay

-

assay

-

assay

≥98% (HPLC)

form

solid

form

-

form

-

form

powder

Quality Level

100

Quality Level

-

Quality Level

-

Quality Level

100

storage temp.

room temp

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

room temp

solubility

DMSO: >10 mg/mL

solubility

-

solubility

-

solubility

DMSO: >10 mg/mL

storage condition

desiccated

storage condition

-

storage condition

-

storage condition

desiccated

Biochem/physiol Actions

Rotigotine hydrochloride is a non-ergolinic D3/D2 and D1-dopamine agonist. It is appropriate for transdermal delivery through skin patches, that has the drug in a silicone-based adhesive matrix.[1]
Rotigotine is a dopamine receptor agonist with preference for D3 receptors over D2 and D1. As such, it is an effective anti-Parkinsonian agent.
Rotigotine is a dopamine receptor agonist with preference for D3 receptors over D2 and D1. As such, it is an effective anti-Parkinsonian agent. Racemic rotigotine is about 50 times as potent as quinpirole, the gold standard D2 agonist.

Features and Benefits

This compound was developed by UCB Inc.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
072M4725V
069K47141
069K4714

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lawrence W Elmer et al.
Parkinsonism & related disorders, 18(5), 488-493 (2012-02-14)
This prospective, open-label extension (SP702; NCT00594165) of a 6-month double-blind, randomized study investigated the long-term safety and tolerability of rotigotine transdermal system in early Parkinson's disease (PD). Patients with early-stage idiopathic PD received transdermal rotigotine for up to 6 years
Nikos Gorgoraptis et al.
Brain : a journal of neurology, 135(Pt 8), 2478-2491 (2012-07-05)
Hemispatial neglect following right-hemisphere stroke is a common and disabling disorder, for which there is currently no effective pharmacological treatment. Dopamine agonists have been shown to play a role in selective attention and working memory, two core cognitive components of
S R Schreglmann et al.
Parkinsonism & related disorders, 18(2), 207-209 (2011-10-28)
Dopaminergic drugs are the mainstay of treatment for restless legs syndrome (RLS). We analyzed the frequency and clinical characteristics of impulse control disorders (ICD) in patients with RLS on transdermal rotigotine treatment. Retrospective case series at a university movement disorder
Santiago Perez-Lloret et al.
Fundamental & clinical pharmacology, 27(1), 81-95 (2012-02-11)
Rotigotine, a non-ergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch has received EMEA marketing authorization for the treatment of adult patients with early or advanced Parkinson's disease (PD) or with moderate to severe
Aiping Wang et al.
Pharmaceutical research, 29(9), 2367-2376 (2012-05-03)
To prepare rotigotine loaded microspheres (RoMS) to achieve continuous dopaminergic stimulation (CDS) for the treatment of Parkinson's disease (PD) and investigate both the therapeutic benefit and inducibility of AIMs of administration of RoMS combination with L-DOPA in 6-OHDA-leisioned rats. Rotigotine
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service